FDA Shortens Amgen Lung Cancer Drug Monitoring

The U.S. Food and Drug Administration (FDA) has greenlit an update to the prescribing information for Amgen's Imdelltra (tarlatamab-dlle). This revision notably shortens the recommended monitoring period for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed after platinum-based chemotherapy.

Initially, patients required 22 to 24 hours of observation following the first two Imdelltra infusions. The updated guidance now mandates a reduced monitoring time of six to eight hours in a suitable healthcare setting for these initial doses. This adjustment, coupled with a follow-up assessment the day after each of the first two doses, aims to ease the burden of extended clinic stays.

For subsequent doses, monitoring requirements are tiered: six to eight hours for the third dose and throughout Cycle 2, decreasing to three to four hours for Cycles 3 and 4, and finally two hours from Cycle 5 onwards. The label continues to emphasize remaining within one hour of medical facilities for 48 hours post-infusion and having a caregiver present. Amgen stated this regulatory decision could simplify care and address practical challenges, potentially enabling more patients to receive treatment closer to home.

Imdelltra functions as a targeted immunotherapy, designed to target DLL3 proteins on tumor cells and CD3 on T cells, thereby activating the immune system against SCLC cells. In January 2025, Amgen received conditional approval for Imdelltra in the UK for ES-SCLC treatment.